1. History
The concept of double outlet right ventricle (DORV) was first described pathologically by Braun et al. in 1952, and Witham systematized its anatomical variants in 1957. In 1972, Lev and colleagues defined DORV as a condition in which both or most of both the aorta and pulmonary artery arise from the right ventricle and proposed an anatomic-physiologic classification based on the location of the ventricular septal defect (VSD). Early surgical repair was performed by Kirklin et al. in 1957, but mortality was very high. Subsequently, with advances in cardiopulmonary bypass technology, intraventricular tunnel repair was established over the 1970s–80s, and excellent results were reported particularly when the VSD was located beneath the aorta (subaortic VSD). In the 1980s, Yacoub and Lecompte applied the arterial switch operation to the Taussig-Bing variant with transposition of the great arteries, greatly improving long-term outcomes. In 2000, the Society of Thoracic Surgeons (STS)/European Association for Cardio-Thoracic Surgery (EACTS) nomenclature database project established an international standard definition and classification of DORV, laying the foundation for multicenter research.
2. Causes
DORV is a multifactorial congenital heart malformation in which genetic and environmental factors act in combination. Genetically, 22q11.2 microdeletion (DiGeorge syndrome, velocardiofacial syndrome) is present in about 5–10%. TBX1 haploinsufficiency causes great artery malalignment by impairing neural crest cell migration, which is critical for outflow tract separation. Transcription factor variants such as GATA4, NKX2-5, HAND2, CITED2 and FOXH1 have also been reported. Associated chromosomal abnormalities include trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and Turner syndrome. Known environmental risk factors include exposure to diabetes in early pregnancy, maternal phenylketonuria, anticonvulsant use (valproic acid, phenytoin), alcohol and retinoic acid exposure. Maternal diabetes increases the risk of DORV 3–5-fold, which is linked to the mechanism by which hyperglycemia inhibits neural crest cell migration.
3. Genetics
The genetic architecture of DORV is broad, ranging from single-gene abnormalities to chromosome-level variants. 22q11.2 deletion is the most frequently reported copy number variant (CNV) in DORV and is confirmed by fluorescence in situ hybridization (FISH) or chromosomal microarray. Among TBX1 single nucleotide polymorphisms (SNPs), c.1223G>A (p.Arg408His), c.541G>A (p.Gly181Ser) and others have been reported to show a cardiac phenotype in functional studies. Heterozygous loss-of-function variants of HAND2 (7q36.1) reproduce the DORV phenotype in mouse models and are also rarely reported in humans. DORV and ventricular septal defects occur in Nkx2-5 conditional knockout mice. Recent genome-wide association studies (GWAS) and exome sequencing (WES) have identified variants in the NODAL signaling pathway (FOXH1, ACVR2B), ciliary genes (ZIC3, CRELD1) and noncoding regulatory regions in complex heart malformations. Because DORV has a high proportion of de novo variants even in non-syndromic cases, application of whole-genome sequencing (WGS) or WES is considered for prenatal genetic testing.
4. General epidemiology
DORV accounts for about 1–1.5% of all congenital heart malformations and is estimated at about 0.57–1.0 per 10,000 live births. In Korea, based on Health Insurance Review & Assessment Service (HIRA) data, about 30–60 new diagnoses are reported annually. Sex differences vary somewhat by specific anatomical variant, but overall the male-to-female ratio is similar or slightly higher in boys. DORV is often associated with heterogeneous complex heart malformations, and DORV is present in 20–30% of asplenia or polysplenia (heterotaxy syndrome). In these cases, additional atrioventricular valve abnormalities, total anomalous pulmonary venous connection (TAPVC), aortic anomalies and others coexist. The Taussig-Bing anomaly accounts for about 15–20% of DORV and is characterized by a subpulmonary VSD and transposition of the great arteries. Non-VSD forms (non-committed VSD) or DORV without a VSD are exceptionally rare, accounting for less than about 3% of the total.
5. Pathophysiology
The heart begins to develop at the end of the third week of embryonic development when two endocardial tubes originating from the lateral plate mesoderm fuse in the midline to form a single heart tube. The heart tube then loops to the right (rightward looping, D-looping) so that the atria, ventricles and outflow tract are arranged in sequence, and outflow tract septation, valve formation and separation of the great vessels are completed through neural crest cell migration and the influx of second heart field (SHF) cells. Transcription factors regulating this process include NKX2-5, GATA4, TBX1, TBX5, HAND1/2 and ISL1, and variants in these genes or environmental disruption constitute the common pathogenetic mechanism of congenital heart malformations.
DORV arises from incomplete progression of conotruncal rotation. In normal development, the conotruncus undergoes a 60° clockwise spiral twist that positions the aorta over the left ventricle and the pulmonary artery over the right ventricle. When neural crest cell migration is impaired, the conal septum forms more anteriorly or to the right of its normal position, so the aortic orifice remains within the right ventricle. In addition, insufficient support of the outflow tract wall by second heart field (SHF)–derived myocardium may cause failure of aortic "commitment" shift. The VSD location determines the final anatomical phenotype and is classified into four types: subaortic, subpulmonary, doubly committed and non-committed (Lev classification). Non-committed VSD is also accompanied by a separate abnormality of ventricular inlet development.
6. Symptoms
The clinical symptoms of DORV span a very wide spectrum depending on VSD location, the degree of pulmonary blood flow and the complexity of associated anomalies. The most common form, with a subaortic VSD (Fallot type), is often accompanied by pulmonary stenosis, so cyanosis is the main symptom, similar to tetralogy of Fallot. Cyanotic spells (tet spells) may occur during exertion or feeding in infancy. In contrast, in the Taussig-Bing variant, with the VSD located beneath the pulmonary artery, pulmonary blood flow is increased and congestive heart failure—tachypnea, diaphoresis, poor feeding, failure to thrive—appears from the neonatal period, while cyanosis is relatively mild. With excessive pulmonary blood flow without pulmonary stenosis, there is a risk of early progression of pulmonary vascular obstructive disease, and cyanosis may worsen rapidly within weeks to months after birth. A heart murmur is heard in all forms, and a paradoxical pattern in which the murmur decreases as pulmonary vascular resistance rises may be seen.
7. Signs
On neonatal physical examination, oxygen saturation measurement (pulse oximetry) is essential for early detection of DORV. Cyanosis is central and observed in the mucous membranes, lips and nails. Differential cyanosis is characteristic of the Taussig-Bing variant: because the aorta lies posterior to the pulmonary artery, the upper limbs receive oxygenated blood and the lower limbs receive deoxygenated blood from the pulmonary artery, so cyanosis of the lower limbs may be prominent. The electrocardiogram mostly shows a right ventricular hypertrophy (RVH) pattern, and with associated left ventricular outflow tract obstruction a left ventricular hypertrophy (LVH) or biventricular hypertrophy pattern appears. Chest X-ray shows increased pulmonary vascular markings (increased pulmonary blood flow type) or decreased markings (Fallot type), and heart size increases when pulmonary hypertension is present. On echocardiography, both the aorta and pulmonary artery arise more than 50% from the right ventricle, and the presence of a subpulmonary conus and loss of fibrous continuity between the two semilunar valves are key findings.
8. Screening
Prenatal screening is performed by detailed fetal echocardiography at 18–22 weeks of gestation. If an abnormality is suspected on the four-chamber view, the outflow tract view is used to confirm whether both great arteries arise from the right ventricle. 3D/4D fetal echocardiography helps define the spatial relationship of the great arteries more clearly. When DORV is suspected, chromosomal microarray including 22q11.2 deletion or whole-exome sequencing is recommended. After birth, the neonatal congenital heart disease screening program (pulse oximetry at 24–48 hours after birth) contributes to early detection of cyanotic DORV. However, in acyanotic cases or those with normal pulmonary blood flow, referral for neonatal echocardiography based on auscultation of a heart murmur becomes the main diagnostic pathway. In high-risk groups (family history of congenital heart malformation, maternal diabetes, 22q11.2-related syndromes), first-trimester fetal nuchal translucency measurement and detailed cardiac ultrasound evaluation are performed preemptively.
9. Diagnosis
The final diagnosis and surgical planning for DORV are made through the following multistep imaging evaluation. Echocardiography is the primary diagnostic tool and comprehensively assesses the right ventricular origin of both great arteries (≥50% override), VSD location (subaortic, subpulmonary, doubly-committed, non-committed), the presence and degree of pulmonary stenosis, atrioventricular valve abnormalities and ventricular function. Cardiac CT angiography (cardiac CTA) is essential for identifying the three-dimensional spatial relationships of the great arteries, anomalous coronary artery origins and anomalous pulmonary venous return, and the latest low-dose protocols are recommended to minimize radiation dose. Cardiac MRI provides information on ventricular volume, function, myocardial characterization and hemodynamics without radiation exposure and is useful for pre- and postoperative assessment. Cardiac catheterization is applied to measure pulmonary vascular resistance (PVR), measure pressures and judge surgical suitability; PVR >8 Wood units/m² is considered a contraindication to complete repair. Genetic testing (chromosomal microarray, WES/WGS) is essential for counseling on associated anomalies and recurrence risk.
10. Treatment
The principle of surgical repair of DORV is to use an intraventricular tunnel so that left ventricular blood is ejected through the aorta, and the surgical approach varies greatly depending on the anatomical variant.
1) VSD-aorta tunnel repair (subaortic VSD, Fallot type)
An intraventricular baffle from the left ventricle to the aorta is placed through the VSD, and if needed, pulmonary stenosis is corrected at the same time (transannular patch or right ventricle–pulmonary artery conduit). Long-term outcomes are best in this form.
2) Arterial switch operation (ASO)—Taussig-Bing variant
In the Taussig-Bing variant (subpulmonary VSD + an arrangement resembling transposition of the great arteries), the ASO developed by Jatene is performed. The ascending aorta and pulmonary artery are transected and switched, and the coronary arteries are transferred to the neo-aorta. The Le Compte maneuver (moving the pulmonary artery anterior to the aorta) is performed concurrently, and the VSD is closed with a patch in the left ventricle–neo-pulmonary artery direction. Early repair within 2 weeks to 2 months after birth is essential to prevent progression of pulmonary vascular disease and preserve left ventricular function.
3) Rastelli procedure—VSD + pulmonary stenosis
It consists of a left ventricle–aorta tunnel + insertion of an external right ventricle–pulmonary artery conduit. The need for conduit replacement (on an average cycle of 10–15 years) is an important long-term management issue.
4) Univentricular palliation
When biventricular repair is not possible (ventricular imbalance, non-committed VSD, atrioventricular valve abnormalities), staged Norwood-Glenn-Fontan surgery is performed.
Postoperative management: heart failure treatment (ACE inhibitors, β-blockers), arrhythmia surveillance (Holter), surveillance for conduit stenosis (echocardiography, CT) and enrollment in an adult transition care program (grown-up congenital heart disease, GUCH) are needed.
11. Prognosis
Survival of DORV after modern surgical repair depends heavily on the anatomical variant and the complexity of associated anomalies. With a subaortic VSD (Fallot type), 30-day mortality after complete repair is about 3–5%, and 20-year survival reaches 80–90%. In the Taussig-Bing variant, 30-day mortality after ASO is 5–10%, and 10-year survival is about 70–85%. When the univentricular pathway (Fontan) is chosen, 10-year survival is 70–80%, but in the long term Fontan-related complications such as protein-losing enteropathy, thrombosis and arrhythmia occur. Risk factors for reoperation include residual VSD shunting, obstruction of the neo-right ventricular outflow tract, conduit stenosis and aortic valve regurgitation. Neurodevelopmental prognosis is associated with cardiopulmonary bypass time, duration of hypothermic circulatory arrest and early age at surgery, and regular neurodevelopmental assessment is recommended. Adult survivors should continue regular follow-up with a cardiologist, preconception genetic counseling and prevention of infective endocarditis.
12. Prevention
Primary prevention of DORV is currently limited, but partial prevention through reduction of known risk factors is possible. Evidence is accumulating that folic acid supplementation of 400–800 μg/day in women planning pregnancy reduces the risk not only of neural tube defects but of congenital heart malformations in general. Optimal preconception glycemic control of diabetes (HbA1c <6.5%) significantly lowers the risk of congenital heart malformations. Drugs toxic to the fetal heart, such as valproic acid, are switched to alternative agents during pregnancy whenever possible. When a 22q11.2 deletion has been identified in the family, or for siblings of DORV patients, prenatal genetic counseling and detailed fetal echocardiography are provided in light of the recurrence risk (3–5%). After a prenatal diagnosis of congenital heart malformation, a collaborative system of pediatric cardiology and pediatric cardiac surgery is established before delivery, and delivery and surgery are planned at a tertiary care center with sufficient experience in corrective surgery. MMR vaccination to prevent rubella is also important as an indirect means of prevention.
References
- Lev M, et al. The pathologic anatomy of the double outlet right ventricle. Am J Cardiol. 1972;29(5):719-725. [PMID 5016980]
- Walters HL 3rd, et al. Congenital Heart Surgery Nomenclature and Database Project: double outlet right ventricle. Ann Thorac Surg. 2000;69(4 Suppl):S249-263. [PMID 10798425]
- Lacour-Gayet F, et al. Surgical management of progressive pulmonary vascular disease in double outlet right ventricle. J Thorac Cardiovasc Surg. 2004;127(4):977-984. [PMID 15052052]
- Bradley TJ, et al. Determinants of repair type, reintervention, and mortality in 393 children with double-outlet right ventricle. J Thorac Cardiovasc Surg. 2007;134(4):967-973. [PMID 17903521]
- Belli E, et al. Surgical options in double outlet right ventricle with non-committed ventricular septal defect. Eur J Cardiothorac Surg. 2008;33(3):399-405. [PMID 18207434]
- Barbero-Marcial M, et al. Intraventricular repair of the double-outlet right ventricle with noncommitted ventricular septal defect. J Thorac Cardiovasc Surg. 2002;124(5):902-908. [PMID 12407374]
- Kleinert S, et al. Profiles of patients with double-outlet right ventricle. Am J Cardiol. 1997;80(8):1064-1068. [PMID 9352981]
- Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39(12):1890-1900. [PMID 12084585]
- Pierpont ME, et al. Genetic basis for congenital heart disease: revisited. Circulation. 2018;138(21):e653-e711. [PMID 30571578]
- Warnes CA, et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease. J Am Coll Cardiol. 2008;52(23):e143-263. [PMID 19038677]